EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vita 34 AG's enterprise value is €95.29 Mil.
Vita 34 AG's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was €-13.22 Mil. Therefore, Vita 34 AG's EV-to-EBITDA for today is -7.21.
The historical rank and industry rank for Vita 34 AG's EV-to-EBITDA or its related term are showing as below:
XTER:V3V'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -249.32 Med: 6.21 Max: 240.91
Current: -7.21
During the past 13 years, the highest EV-to-EBITDA of Vita 34 AG was 240.91. The lowest was -249.32. And the median was 6.21.
XTER:V3V's EV-to-EBITDA is ranked worse than 100% of 460
companies
in the Healthcare Providers & Services industry
Industry Median: 13.06
vs XTER:V3V: -7.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-06), Vita 34 AG's stock price is €4.66.
Vita 34 AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €-1.568. Therefore, Vita 34 AG's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Vita 34 AG EV-to-EBITDA Historical Data
The historical data trend for Vita 34 AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vita 34 AG's EV-to-EBITDA
For the Medical Care Facilities subindustry, Vita 34 AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita 34 AG's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Vita 34 AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vita 34 AG's EV-to-EBITDA falls into.
Vita 34 AG EV-to-EBITDA Calculation
Vita 34 AG's EV-to-EBITDA for today is calculated as:
Vita 34 AG's current Enterprise Value is €95.29 Mil.
Vita 34 AG's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita 34 AG (XTER:V3V) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vita 34 AG's share price for today is €4.66.
Vita 34 AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.568.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Vita 34 AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Vita 34 AG is an umbilical cord blood bank. It supplies cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue. The Group has two strategic areas that constitute the Group's reportable segments. Both segments are active in the field of stem cell banking, but differ in their organizational and operational structure with separate financial information. The products and services of the two segments correspond to the service portfolios of the two subgroups PBKM and Vita 34. It operates in Germany, Spain, and other international countries, of which maximum revenue is derived from the business operations in Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTER:V3V has been successfully added to your 